Terns Pharmaceuticals Releases Clinical Progress Presentation

Summary

Terns Pharmaceuticals Inc. (Nasdaq: TERN) has released a corporate presentation detailing clinical progress up to June 2025. The company is developing Tern-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), currently in Phase 1, and Tern-601, an oral GLP-1 receptor agonist for obesity, currently in Phase 2 trials. Key milestones are expected in Q4 2025. Terns has $334 million in cash reserves to support its pipeline until 2028.Reuters

Impact Analysis

{